| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-170 |
Sentence |
denotes |
Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. |
| TextSentencer_T2 |
171-182 |
Sentence |
denotes |
BACKGROUND: |
| TextSentencer_T3 |
183-283 |
Sentence |
denotes |
Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation. |
| TextSentencer_T4 |
284-493 |
Sentence |
denotes |
After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis. |
| TextSentencer_T5 |
494-507 |
Sentence |
denotes |
OBSERVATIONS: |
| TextSentencer_T6 |
508-736 |
Sentence |
denotes |
A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%). |
| TextSentencer_T7 |
737-941 |
Sentence |
denotes |
Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus. |
| TextSentencer_T8 |
942-954 |
Sentence |
denotes |
CONCLUSIONS: |
| TextSentencer_T9 |
955-1042 |
Sentence |
denotes |
Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome. |
| TextSentencer_T10 |
1043-1209 |
Sentence |
denotes |
These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators. |
| TextSentencer_T11 |
1210-1421 |
Sentence |
denotes |
Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators. |
| T1 |
0-170 |
Sentence |
denotes |
Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. |
| T2 |
171-182 |
Sentence |
denotes |
BACKGROUND: |
| T3 |
183-283 |
Sentence |
denotes |
Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation. |
| T4 |
284-493 |
Sentence |
denotes |
After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis. |
| T5 |
494-507 |
Sentence |
denotes |
OBSERVATIONS: |
| T6 |
508-736 |
Sentence |
denotes |
A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%). |
| T7 |
737-941 |
Sentence |
denotes |
Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus. |
| T8 |
942-954 |
Sentence |
denotes |
CONCLUSIONS: |
| T9 |
955-1042 |
Sentence |
denotes |
Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome. |
| T10 |
1043-1209 |
Sentence |
denotes |
These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators. |
| T11 |
1210-1421 |
Sentence |
denotes |
Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators. |